[HTML][HTML] Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)–related interstitial lung disease/pneumonitis—focus on proactive monitoring, diagnosis …
Abstract Trastuzumab deruxtecan (T-DXd; DS-8201) is an antibody-drug conjugate targeting
human epidermal growth factor receptor 2. Interstitial lung disease (ILD)/pneumonitis is an …
human epidermal growth factor receptor 2. Interstitial lung disease (ILD)/pneumonitis is an …
Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low–expressing advanced breast cancer: results from a phase Ib study
S Modi, H Park, RK Murthy, H Iwata… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE Trastuzumab deruxtecan (T-DXd, formerly DS-8201a) is a novel human
epidermal growth factor receptor 2 (HER2)-targeted antibody drug conjugate (ADC) with a …
epidermal growth factor receptor 2 (HER2)-targeted antibody drug conjugate (ADC) with a …
[HTML][HTML] Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies
Introduction This pooled analysis of nine phase I and II trastuzumab deruxtecan (T-DXd)
monotherapy studies described drug-related interstitial lung disease (ILD)/pneumonitis in …
monotherapy studies described drug-related interstitial lung disease (ILD)/pneumonitis in …
[HTML][HTML] Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment
Background Drug-induced interstitial lung disease (DIILD) is a form of interstitial lung
disease resulting from exposure to drugs causing inflammation and possibly interstitial …
disease resulting from exposure to drugs causing inflammation and possibly interstitial …
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion …
K Tamura, J Tsurutani, S Takahashi, H Iwata… - The Lancet …, 2019 - thelancet.com
Background Trastuzumab deruxtecan (DS-8201a) is a novel HER2-targeted antibody–drug
conjugate with a humanised anti-HER2 antibody, cleavable peptide-based linker, and …
conjugate with a humanised anti-HER2 antibody, cleavable peptide-based linker, and …
Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: a review
Importance In the past decade, ERBB2 (formerlyHER2)–directed antibody-drug conjugates
(ADCs) have substantially changed treatment of both advanced and early-stage ERBB2 …
(ADCs) have substantially changed treatment of both advanced and early-stage ERBB2 …
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study
K Shitara, H Iwata, S Takahashi, K Tamura… - The Lancet …, 2019 - thelancet.com
Background Trastuzumab deruxtecan (DS-8201a) is a novel HER2-targeted antibody–drug
conjugate with a humanised anti-HER2 antibody, cleavable peptide-based linker, and …
conjugate with a humanised anti-HER2 antibody, cleavable peptide-based linker, and …
Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: a …
T Johkoh, KS Lee, M Nishino, WD Travis, JH Ryu… - Radiology, 2021 - pubs.rsna.org
Use of molecular targeting agents and immune checkpoint inhibitors (ICIs) has increased
the frequency and broadened the spectrum of lung toxicity, particularly in patients with …
the frequency and broadened the spectrum of lung toxicity, particularly in patients with …
[HTML][HTML] Trastuzumab deruxtecan-induced interstitial lung disease/pneumonitis in ERBB2-positive advanced solid malignancies: a systematic review
Z Abuhelwa, A Alloghbi, A Alqahtani, M Nagasaka - Drugs, 2022 - Springer
Abstract Background and Objective Trastuzumab deruxtecan (T-DXd) is a novel anti-ERBB2
antibody drug conjugate that appears to be associated with an increased risk of lung toxicity …
antibody drug conjugate that appears to be associated with an increased risk of lung toxicity …